Bioscript has made its fourth acquisition since 2021. Enzyme Communications follows Meridan, Fortis and Valid Insight.
Enzyme adds scientific content creation and storytelling expertise.
Gabrielle Silver, CEO of Bioscript Group, said: “Enzyme Communications is a very welcome addition to our portfolio as we continue our journey to become leaders in scientific communications for the life sciences sector.”
All of Bioscript’s acquisitions to date are focussed on health, science, life sciences or bio.